<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031430</url>
  </required_header>
  <id_info>
    <org_study_id>PREMOM II</org_study_id>
    <nct_id>NCT04031430</nct_id>
  </id_info>
  <brief_title>PREMOM II: Pregnancy Remote Monitoring of Women With Gestational Hypertensive Disorders</brief_title>
  <acronym>PREMOM II</acronym>
  <official_title>PREMOM II: Pregnancy Remote Monitoring of Women With Gestational Hypertensive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Lucas Brugge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is thoroughly evaluate the added value of telemonitoring (TM)
      program for women at risk for gestational hypertensive disorders (GHD), by investigating it
      impact on prenatal follow-up, health outcomes for mother and child, costs and satisfaction,
      and by specifically investigating what are the major contributors to this added value.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational age (GA)</measure>
    <time_frame>Throug study completion, from the first contact with the gynaecologist (after fertilization) untill 34 weeks of gestation.</time_frame>
    <description>Throug study completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hospitalization</measure>
    <time_frame>Numbers of hospitalization during pregnancy (Numeric. Available by hospital details of every patient who is included in the study. From the moment of hospitalization until the moment of discharge is 1 hospitalization.</time_frame>
    <description>Through study completion, from 32 weeks of gestation untill 34 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of prenatal consults</measure>
    <time_frame>through study completion,</time_frame>
    <description>prenatal follow- up, numeric value, every consult during pregnancy from the first consultation until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ultrasounds</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric value, every ultrasound during pregnancy from the first consultation until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of CTG's</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric value, every CTG during pregnancy from the first consultation until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospitalizations of the mother at the MIC department</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric value, every hospitalization at the MIC during pregnancy from the first consultation until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days admitted to the MIC</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric value, amount of days admitted to the MIC from the first consultation unitil delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of medication adaptations during pregnancy</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric value, every change from no medication intake/a specific medciation at a specific dose to another medication intake at a specific dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of gestational hypertensive disorders</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric, the diagnoses of gestational hypertension/pre-eclampsia/HELLP during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of delivery</measure>
    <time_frame>through study completion</time_frame>
    <description>categorical (spontaneous, induced, primary section)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of delivery</measure>
    <time_frame>through study completion</time_frame>
    <description>categorical (spontaneous, induced, primary section) from birth until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>through study completion</time_frame>
    <description>categorical (vaginal, instrumental, primary/secondary section) from birth until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birthweight</measure>
    <time_frame>through study completion</time_frame>
    <description>gram from birth until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar at 1' and 5'</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric (0-10) from birth until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to the neonatal intensive care (NIC)</measure>
    <time_frame>through study completion</time_frame>
    <description>categorical(Yes/no) from birth until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days admitted to the NIC</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric value, amount of days admidtted to the NIC, from birth until discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost for the health care services (HCS)</measure>
    <time_frame>through study completion</time_frame>
    <description>Costs of the prenatal care as described in Secondary outcomes (1) and costs for the care during and after the delivery as described in Secondary outcomes (2), which are divided in: costs for the HCS, costs for the patient, costs for the RIZIV. All costs will be collected in Euros. rom the first contact with the gynaecologist until the discharge from the hospital of both the mother and the neonate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of phone calls from the patient to the midwife for technical issues</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric scale, contributor to the added value of TM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of phone calls from the patient to the midwife for medical issues</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric scale, contributor to the added value of TM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of phone calls from the midwife to the patient for technical issues</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric scale, contributor to the added value of TM from the inclusion in the study until the moment of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of phone calls from the midwife to the patient for medical issues</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric scale, contributor to the added value of TM from the inclusion in the study until the moment of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of starts/adjustments to the antihypertensive medication</measure>
    <time_frame>through study completion</time_frame>
    <description>numeric scale, contributor to the added value of TM from the inclusion in the study until the moment of delivery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6107</enrollment>
  <condition>Gestational Hypertension</condition>
  <arm_group>
    <arm_group_label>telemonitoring group (TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient self-monitoring group (PSM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group (CC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Telemonitoring</intervention_name>
    <description>Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.</description>
    <arm_group_label>Patient self-monitoring group (PSM)</arm_group_label>
    <arm_group_label>telemonitoring group (TM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - a risk &gt; 1/100 on the Fetal Medicine Foundation (FMF) tool, which is used from the
        following website: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester

        Exclusion Criteria:

          -  congenital malformations of the newborn,

          -  pregnant women who doesn't have a Smartphone,

          -  pregnant women &lt; 18 years old,

          -  pregnant women who doesn't understand the Dutch/French/English language. -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried Gyselaers, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorien Lanssens, dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilfried Gyselaers, prof. dr.</last_name>
    <phone>+ 32 89 32 15 57</phone>
    <email>wilfried.gyselaers@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorien Lanssens, dr.</last_name>
    <phone>+ 32 89 32 15 57</phone>
    <email>dorien.lanssens@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Jacquemyn, prof.dr.</last_name>
      <phone>+32 34 58 40 04</phone>
      <email>yves.jacquemyn@uza.be</email>
    </contact>
    <investigator>
      <last_name>Yves Jacquemyn, prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas Brugge - Oostende</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Logghe, dr.</last_name>
      <phone>+32 50 36 50 80</phone>
      <email>hilde.logghe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hilde Logghe, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge - Oostende</name>
      <address>
        <city>Brugge</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lebbe, dr.</last_name>
      <email>barbara.lebbe@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Barbara Lebbe, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric de Jonge, prof.dr.</last_name>
      <phone>+32 89 32 50 50</phone>
      <email>eric.dejonge@zol.be</email>
    </contact>
    <contact_backup>
      <last_name>Dorien Lanssens, dr.</last_name>
      <phone>+32 89 32 15 57</phone>
      <email>dorien.lanssens@uhasselt.be</email>
    </contact_backup>
    <investigator>
      <last_name>Eric de Jonge, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Devlieger, prof. dr.</last_name>
      <phone>+32 16 34 42 04</phone>
      <email>roland.devlieger@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Roland Devlieger, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Wilfried Gyselaers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>remote monitoring</keyword>
  <keyword>gestational hypertensive disorders</keyword>
  <keyword>pregnancy outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

